AKEBIA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
AKEBIA THERAPEUTICS, INC. (AKBA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$20.04 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-07
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$20.04M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$8.58M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$17.98M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$14.49M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$135.75M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$60.72M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2014 was -$123.93M.
- AKEBIA THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2013 was -$69.05M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 85 month |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | -$20.04M 10-Q · filed 2024-11-07 | -$28.62M derived: sum of 2 quarters · filed 2024-11-07 | -$46.61M 10-Q · filed 2024-11-07 | ||||||
| 2024-06-30 | -$8.58M 10-Q · filed 2024-08-08 | -$26.57M 10-Q · filed 2024-08-08 | |||||||
| 2024-03-31 | -$17.98M 10-Q · filed 2024-05-09 | ||||||||
| 2023-09-30 | -$14.49M 10-Q · filed 2024-11-07 | -$25.66M derived: sum of 2 quarters · filed 2024-11-07 | -$52.54M 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | -$11.17M 10-Q · filed 2024-08-08 | -$38.05M 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | -$26.88M 10-Q · filed 2024-05-09 | -$26.22M 10-Q · filed 2023-05-08 | |||||||
| 2022-09-30 | -$54.10M 10-Q · filed 2023-11-08 | -$51.87M 10-Q · filed 2022-11-03 | -$24.65M derived: sum of 2 quarters · filed 2023-11-08 | -$88.16M 10-Q · filed 2023-11-08 | -$85.01M 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $29.45M 10-Q · filed 2023-08-28 | $29.28M 10-Q · filed 2022-08-04 | -$34.06M 10-Q · filed 2023-08-28 | -$33.15M 10-Q · filed 2022-08-04 | |||||
| 2022-03-31 | -$63.51M 10-Q · filed 2023-08-28 | -$62.42M 10-Q · filed 2023-05-08 | |||||||
| 2021-09-30 | -$59.54M 10-Q · filed 2022-11-03 | -$142.58M derived: sum of 2 quarters · filed 2022-11-03 | -$212.16M 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | -$83.04M 10-Q · filed 2022-08-04 | -$152.62M 10-Q · filed 2022-08-04 | |||||||
| 2016-12-31 | -$135.75M 10-K · filed 2017-03-06 | ||||||||
| 2015-12-31 | -$19.86M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$39.33M derived: sum of 2 quarters · filed 2017-03-06 | -$50.02M derived: sum of 3 quarters · filed 2017-03-06 | -$60.72M 10-K · filed 2017-03-06 | |||||
| 2015-09-30 | -$19.48M 10-Q · filed 2015-11-09 | -$30.16M derived: sum of 2 quarters · filed 2015-11-09 | -$40.86M 10-Q · filed 2015-11-09 | -$51.23M derived: sum of 4 quarters · filed 2017-03-06 | |||||
| 2015-06-30 | -$10.69M 10-Q · filed 2015-08-11 | -$21.38M 10-Q · filed 2015-08-11 | -$31.75M derived: sum of 3 quarters · filed 2017-03-06 | -$41.10M derived: sum of 4 quarters · filed 2017-03-06 | |||||
| 2015-03-31 | -$10.70M 10-Q · filed 2015-05-11 | -$21.07M derived: sum of 2 quarters · filed 2017-03-06 | -$30.41M derived: sum of 3 quarters · filed 2017-03-06 | -$38.03M derived: sum of 4 quarters · filed 2017-03-06 | |||||
| 2014-12-31 | -$10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$19.72M derived: sum of 2 quarters · filed 2017-03-06 | -$27.34M derived: sum of 3 quarters · filed 2017-03-06 | -$123.93M 10-K · filed 2017-03-06 | -$123.93M 10-K · filed 2015-03-04 | ||||
| 2014-09-30 | -$9.35M 10-Q · filed 2015-11-09 | -$9.35M 10-Q · filed 2014-11-10 | -$16.97M derived: sum of 2 quarters · filed 2015-11-09 | -$113.56M 10-Q · filed 2015-11-09 | -$113.56M 10-Q · filed 2014-11-10 | -$122.54M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-06-30 | -$7.62M 10-Q · filed 2015-08-11 | -$7.62M 10-Q · filed 2014-08-11 | -$104.22M 10-Q · filed 2015-08-11 | -$104.21M 10-Q · filed 2014-08-11 | -$113.19M derived: sum of 3 quarters · filed 2016-03-14 | -$119.70M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-03-31 | -$96.60M 10-Q · filed 2015-05-11 | -$96.60M 10-Q · filed 2014-05-12 | -$105.57M derived: sum of 2 quarters · filed 2016-03-14 | -$112.09M derived: sum of 3 quarters · filed 2016-03-14 | -$164.18M derived: sum of 4 quarters · filed 2016-03-14 | -$226.97M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | -$8.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$15.49M derived: sum of 2 quarters · filed 2016-03-14 | -$67.58M derived: sum of 3 quarters · filed 2016-03-14 | -$69.05M 10-K · filed 2016-03-14 | -$69.05M 10-K · filed 2015-03-04 | ||||
| 2013-09-30 | -$6.52M 10-Q · filed 2014-11-10 | -$58.61M derived: sum of 2 quarters · filed 2014-11-10 | -$60.08M 10-Q · filed 2014-11-10 | ||||||
| 2013-06-30 | -$52.10M 10-Q · filed 2014-08-11 | -$53.56M 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | -$1.47M 10-Q · filed 2014-05-12 | ||||||||
| 2012-12-31 | -$11.52M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |